Andrew discusses the controversy surrounding stem cell treatments in the United States, highlighting the legal restrictions and lack of regulatory framework. He questions why countries like Japan and Dubai have approved these treatments while the US has not, suggesting lobbying and pharmaceutical interests as possible factors.
